Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 26.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | hat are associated with, the Reduction. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 16.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 05.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
| 30.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
Stammdaten
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Unternehmen & Branche
| Name | Nkarta, Inc. |
|---|---|
| Ticker | NKTX |
| CIK | 0001787400 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 187,9 Mio. USD |
| Beta | 0,67 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -104,084,000 | -1.41 | 404,209,000 | 312,325,000 |
| 2025-09-30 | 10-Q | -21,715,000 | -0.29 | 427,236,000 | 337,900,000 | |
| 2025-06-30 | 10-Q | -22,977,000 | -0.31 | 448,312,000 | 357,668,000 | |
| 2025-03-31 | 10-Q | -31,983,000 | -0.43 | 470,609,000 | 378,805,000 | |
| 2024-12-31 | 10-K | 0 | -108,790,000 | -1.60 | 501,203,000 | 407,976,000 |
| 2024-09-30 | 10-Q | -28,344,000 | -0.39 | 532,034,000 | 430,873,000 | |
| 2024-06-30 | 10-Q | -24,993,000 | -0.34 | 554,086,000 | 453,184,000 | |
| 2024-03-31 | 10-Q | -29,518,000 | -0.58 | 576,936,000 | 473,651,000 | |
| 2023-12-31 | 10-K | -117,501,000 | -2.40 | 378,885,000 | 273,285,000 | |
| 2023-09-30 | 10-Q | -25,645,000 | -0.52 | 405,864,000 | 296,816,000 | |
| 2023-06-30 | 10-Q | -33,287,000 | -0.68 | 429,038,000 | 317,978,000 | |
| 2023-03-31 | 10-Q | -30,815,000 | -0.63 | 458,169,000 | 346,646,000 | |
| 2022-12-31 | 10-K | -113,837,000 | -2.61 | 472,938,000 | 372,207,000 | |
| 2022-09-30 | 10-Q | -28,345,000 | -0.58 | 503,799,000 | 399,264,000 | |
| 2022-06-30 | 10-Q | -26,923,000 | -0.61 | 503,641,000 | 421,041,000 | |
| 2022-03-31 | 10-Q | -25,987,000 | -0.79 | 306,299,000 | 228,706,000 | |
| 2021-12-31 | 10-K | 0 | -86,075,000 | -2.62 | 273,903,000 | 250,967,000 |
| 2021-09-30 | 10-Q | -22,353,000 | -0.68 | 292,465,000 | 270,011,000 | |
| 2021-06-30 | 10-Q | -21,535,000 | -0.66 | 309,111,000 | 288,382,000 | |
| 2021-03-31 | 10-Q | -19,373,000 | 325,692,000 | 305,990,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | HASTINGS PAUL J | Director, Officer, Chief Executive Officer | Open Market Sale | -26,046 | 2.07 | -53,915.22 | -235,1% | |
| 2026-01-15 | Mahmood Nadir | Officer, President | Open Market Sale | -5,649 | 2.07 | -11,693.43 | -51,0% | |
| 2025-06-18 | HASTINGS PAUL J | Director, Officer, Chief Executive Officer | Open Market Sale | -1,790 | 1.79 | -3,204.10 | -14,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.